A massive undertaking involving more than 1,300 scientists from
37 countries reported in 23 papers shows the results of analyzing 47 million
genetic changes in 2,600 genomes of 38 different tumor types. The Pan-Cancer
Analysis of Whole Genomes (PCAWG) presented what the researchers called “the
most comprehensive study of whole cancer genomes to date.”
Taking advantage
of the latest sequencing and computational informatics technologies, the
researchers, divided into 16 working groups, opened doors to the genetic
complexities and commonalities in cancer, and offered insights that could spur
further discoveries and eventual treatments.
PCAWG analyzed whole genomes
rather than the more common approach of sequencing only protein-coding regions.
They produced 1,188 tumor transcriptomes to link RNA and DNA alterations and
explored genetic drivers, tumor signatures, and virus DNA found in cancers.
These analyses generated more than 800 terabytes of data, roughly equivalent to
the storage required for 200,000 movies.
PCAWG found cancer-driver mutations
for 95% of cases, and that on average each cancer genome has four or five
drivers. Sizable minorities of cancers showed signs of chromoplexy (17.8%) or
chromothripsis (22.3%), reflecting complex and chaotic rearrangement processes.
The researchers found that genetic changes leading to cancer occur early
on—sometimes decades in advance of diagnosis.
The investigation also
uncovered genetic drivers in noncoding DNA, like noncoding regions of the
tumor-suppressor gene TP53 and of the telomerase gene TERT. Another PCAWG team
characterized mutational signatures using more than 84 million somatic mutations
from 4,645 whole-genome and 19,184 exome sequences to describe 81 signatures
including single- doublet- and clustered-base-substitutions as well as small
insertion-and-deletion signatures, many not previously identified. In a first,
another team identified 16 structural variants involving large
rearrangements.
An analysis of viruses associated with cancer highlighted the
prevalence of Epstein–Barr virus, hepatitis B virus, and human
papillomavirus.
All the PCAWG papers, published in Nature and related
journals, are open access at nature.com/collections/afdejfafdb. The researchers’
raw genome sequencing data and other resources also are available to
researchers.
OPIOID POISONINGS WORSENING IN CHILDREN,
ADOLESCENTS
About one-quarter of opioid poisonings occur in children
and adolescents, and poisoning incidents have become more severe in recent
years, according to an abstract presented at the Society of Critical Care
Medicine's annual congress. The retrospective study of more than 750,000 opioid
poisoning cases reported to the National Poison Data System from 2005 to 2018
found that 27.5% (207,543) of cases occurred in patients younger than age
19.
Trend analysis over three eras (2005–2009, 2010–2014, and 2015–2018)
showed that the percentage of patients admitted to critical care units and
deaths increased over time; 6.6%, 8.5%, and 9.6% and 0.18%, 0.20%, and 0.28%,
respectively. The probability of having a moderate or major effect also rose, by
0.55% and 0.11%, respectively.
Opioid poisonings with the intent of
committing suicide increased over the three time periods, from 13.9% to
21.2%.
In a separate published report, the researchers said they observed two
peak age distributions for opioid poisonings, in children from newborns to age 4
and in teenagers from 15 to almost 19.
EMERGENCY DEPARTMENTS
OVER-TEST FOR SUSPECTED PULMONARY EMBOLISM
Computed tomographic
pulmonary angiography (CTPA) is overused in the diagnostic workup of pulmonary
embolism (PE), underscoring “the urgent need for dissemination and
implementation of protocols to reduce low-yield CTPA scanning,” including
D-dimer testing, according to the authors of a study examining emergency
department (ED) practices involving PE-related testing (Circ Cardiovasc Qual
Outcomes 2020;13:e005753).
The study, a cross-sectional analysis of
electronic health record and billing data from 16 EDs in Indiana and 11
hospitals in the Dallas-Fort Worth area, identified ED patients who underwent
any of the following, including D-dimer testing, CTPA, scintillation ventilation
perfusion lung scanning, or pulmonary angiography. Out of 1.83 million patient
encounters, 5.3% had a diagnostic test for PE. Nearly 60% of all patients who
had tests for PE underwent CTPA without D-dimer testing. About 21% of CTPA took
place in women younger than age 45, who are at greater risk of cancer from CTPA
radiation exposure, according to the authors.
The pooled diagnostic yield of
CTPA for PE was 3.1%, with a 1.3% rate in Indiana EDs, and a 4.8% rate in
Dallas-Fort Worth facilities.
Patients in Indiana were less likely than those
in Dallas-Fort Worth to receive D-dimer testing before CTPA (30% versus 52%,
respectively), possibly reflecting the impact of a targeted quality improvement
initiative that had taken place in Dallas-Fort Worth to increase use of D-dimer
testing in low-risk patients.
The data imply that “D-dimer ordering
correlates with an increased yield rate of PE on CTPA,” wrote the investigators.
“This relationship suggests but does not prove a positive cause-effect
relationship between rate of D-dimer ordering and PE yield.”